Pear extends digital therapeutics partnership with Spero
pharmaphorum
JANUARY 5, 2023
The deal centres on reSET and reSET-O, Pear’s cognitive behavioural therapy (CBT) based programmes, for people living with substance and opioid use disorders, respectively, which have been approved by the FDA as an adjunct to outpatient treatment. Pear secured approval for reSET-O in the following year. “We
52 
Let's personalize your content